Clinical Data competitors

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Officer, and was appointed Chairman of the Board of Directors in 2015. During Mr. Hoppenot’s tenure, the Company has tripled the number of clinical candidates in its portfolio, expanding beyond oncology to include research and development in inflammation & autoimmunity. Under his leadership, revenue has increased by over 400 percent, which includes the addition of two new revenue streams; and, with a goal to deliver medicines to patients worldwide, the Company has expanded geographically beyond the U.S. to include operations in 10 EU countries and Japan. Prior to joining Incyte, Mr. Hoppenot was the President of Novartis Oncology. Prior to joining Novartis in 2003, Mr. Hoppenot started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the U.S. Oncology business unit. Mr. Hoppenot holds a diploma from ESSEC Business School.

Reshma Kewalramani (born 1973), is the president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts, as of April 1, 2020. She is the first female CEO of a large US biotech company. She was previously the chief medical officer and vice president of global medicines development and medical affairs at Vertex.

Richard L Feinstein is a VP:Finance/CFO at ENZON PHARMACEUTICALS, INC.; Chief Financial Officer at USA Fitness Corps; and Board Member at USA Fitness Corps and is based in Greater New York City Area. He has worked as VP:Finance/Principal Financial Ofcr at ENZON PHARMACEUTICALS, INC.; Partner at KPMG; and CFO/Consultant at ImageProtect. Richard works or has worked as MEMBER at Association For A Better New York. He studied at Pace University.

Llew Keltner is the co-founder and CEO of [Light Sciences Oncology](https://www.crunchbase.com/organization/light-sciences-oncology), a company that develops light-activated drug products to treat patients with solid tumor cancers. He also works as a consultant at ImmunoVaccine. Prior to that, Keltner held several senior executive positions at AgonOx, MetaStat, Light Sciences Corporation. He also is a director at a number of companies, including Raptor Pharmaceuticals, Infostat, Oregon Life Sciences, LKHealthnet, Goodwell Technologies, RxBazaar, and Gray Peaks. Keltner holds a medical degree and a PhD from Case Western Reserve University.